AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 0
Study 21308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Matricaria recutita
Number of subjects: 0
Study 21308265 — intervention group
Group type: COMPARATOR
Intervention: Standard anxiolytics (benzodiazepines, buspirone, antidepressants)
Number of subjects: 0
Study 21308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Galphimia glauca, Passiflora incarnata, Valeriana officinalis
Number of subjects: 0
Study 17267292 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25 mg midazolam
Number of subjects: 28
Study 17267292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75 mg midazolam
Number of subjects: 28
Study 17267292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16060741 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstractly worded messages
Number of subjects: 0
Study 16060741 — intervention group
Group type: COMPARATOR
Intervention: Concretely worded messages
Number of subjects: 0
Study 12378657 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid intravenous fluid
Number of subjects: 0
Study 12378657 — intervention group
Group type: COMPARATOR
Intervention: Colloid intravenous fluid
Number of subjects: 0
Study 9988284 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors for left ventricular dysfunction (LVD) and/or diabetes mellitus (DM)
Number of subjects: 407
Study 9988284 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin for history of myocardial infarction (MI)
Number of subjects: 407
Study 9988284 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for chronic atrial fibrillation (AF)
Number of subjects: 407
Study 9988284 — intervention group
Group type: EXPERIMENTAL
Intervention: Any or all indicated medications
Number of subjects: 407
Study 7763057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved embryos
Number of subjects: 91
Study 7763057 — intervention group
Group type: COMPARATOR
Intervention: Control (normal conception)
Number of subjects: 91
Study 1967677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hydrocortisone (200 mg)
Number of subjects: 25
Study 1967677 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal hydrocortisone (200 mg)
Number of subjects: 25
Study 1967677 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 25
Study 7375869 — intervention group
Group type: EXPERIMENTAL
Intervention: Biarison (600-900 mg daily)
Number of subjects: 55
Study 7375869 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50-100 mg daily)
Number of subjects: 55
Study 7375869 — intervention group
Group type: EXPERIMENTAL
Intervention: Biarison (used in treatment of active SLE)
Number of subjects: 55
Study 30461337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg once daily
Number of subjects: 220
Study 26989845 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal frame (intervention to reduce psychological distance)
Number of subjects: 333
Study 26989845 — intervention group
Group type: COMPARATOR
Intervention: Distal frame (control to increase psychological distance)
Number of subjects: 333
Study 25464263 — intervention group
Group type: EXPERIMENTAL
Intervention: Three lead ECG screening
Number of subjects: 1003
Study 22925993 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 64
Study 22925993 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation
Number of subjects: 64
Study 22925993 — intervention group
Group type: COMPARATOR
Intervention: Overall assessment
Number of subjects: 64
Study 20204674 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (3 mg/m² i.v. every 21 days) plus gefitinib (250 mg p.o. daily)
Number of subjects: 76
Study 20204674 — intervention group
Group type: COMPARATOR
Intervention: Raltitrexed (3 mg/m² i.v. every 21 days)
Number of subjects: 76
Study 18809275 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (0.5 g/day for two days, followed by 1g/day for two days, and then 2g/day for 10 days)
Number of subjects: 29
Study 18809275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18809275 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (during exploratory analysis)
Number of subjects: 29
Study 16445340 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task balance training
Number of subjects: 3
Study 16445340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training under a fixed-priority instructional set
Number of subjects: 3
Study 16445340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training under a variable-priority instructional set
Number of subjects: 3
Study 12612227 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduling an appointment at the time of an ED visit
Number of subjects: 278
Study 12612227 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scheduling assistance)
Number of subjects: 278
Study 12612227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 278
Study 12612227 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278
Study 12612227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 278
Study 10848879 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol, administered either once daily (OD) or twice daily (BID)
Number of subjects: 19
Study 10848879 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol
Number of subjects: 19
Study 9019175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 40
Study 9019175 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1 mg/kg
Number of subjects: 40
Study 1584737 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization
Number of subjects: 39
Study 1584737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 4064277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 13
Study 4064277 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 13
Study 4064277 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume loading
Number of subjects: 13
Study 29460811 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscosity-regulating pectin solution (VREF group, n = 15)
Number of subjects: 34
Study 29460811 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteral nutrition administration (Control group, n = 12)
Number of subjects: 34
Study 26764413 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 2×7.5 mg
Number of subjects: 21
Study 26764413 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 25018120 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) 0.5 mL intramuscularly (containing 40, 8, and 32 D antigen units for serotypes 1, 2, and 3)
Number of subjects: 450
Study 25018120 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 450
Study 22199171 — intervention group
Group type: EXPERIMENTAL
Intervention: cerebellar continuous theta burst stimulation (cTBS)
Number of subjects: 30
Study 22199171 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no stimulation)
Number of subjects: 30
Study 22199171 — intervention group
Group type: EXPERIMENTAL
Intervention: cerebellar cTBS
Number of subjects: 30
Study 22199171 — intervention group
Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 30
Study 19446951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate 800 mg/d
Number of subjects: 135
Study 19446951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 19446951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 15 mg/d
Number of subjects: 135
Study 17661792 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin re-uptake inhibitor (SSRI) treatment
Number of subjects: 8
Study 17661792 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8
Study 17661792 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute stroke and PC
Number of subjects: 8
Study 15640476 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg Zn daily)
Number of subjects: 400
Study 15640476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 12195349 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir in combination with either ritonavir or nelfinavir, plus delavirdine, adefovir, or both; duration: 48 weeks
Number of subjects: 105
Study 11551136 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 11551136 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0
Study 11551136 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment after neoadjuvant chemotherapy
Number of subjects: 0
Study 9923574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment with serum concentrations above 7 ng/ml
Number of subjects: 106
Study 9923574 — intervention group
Group type: COMPARATOR
Intervention: Tacrine treatment with serum concentrations below 7 ng/ml
Number of subjects: 106
Study 9923574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment with serum concentrations above 5 ng/ml
Number of subjects: 106
Study 9923574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment with serum concentrations above 9 ng/ml
Number of subjects: 106
Study 8091959 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of craniomandibular disorders (CMD)
Number of subjects: 364
Study 3073322 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 10
Study 3073322 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg morphine
Number of subjects: 10
Study 3073322 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg new analgesic
Number of subjects: 10
Study 3073322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg new analgesic
Number of subjects: 10
Study 3073322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29956471 — intervention group
Group type: EXPERIMENTAL
Intervention: octenidine-based hydrogel wound dressing
Number of subjects: 45
Study 29956471 — intervention group
Group type: COMPARATOR
Intervention: standard postoperative wound dressing
Number of subjects: 45
Study 28667705 — intervention group
Group type: EXPERIMENTAL
Intervention: More mental effort on a writing task
Number of subjects: 97
Study 28667705 — intervention group
Group type: COMPARATOR
Intervention: Less mental effort on a writing task
Number of subjects: 97
Study 28667705 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional images
Number of subjects: 97
Study 28667705 — intervention group
Group type: COMPARATOR
Intervention: Neutral images
Number of subjects: 97
Study 26444692 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered Crystalloid
Number of subjects: 2278
Study 26444692 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 2278
Study 22595934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost ophthalmic solution
Number of subjects: 184
Study 22595934 — intervention group
Group type: COMPARATOR
Intervention: Xalatan
Number of subjects: 184
Study 22595934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 184
Study 21203877 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° rotation technique
Number of subjects: 126
Study 21203877 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (control)
Number of subjects: 126
Study 18461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard individual test-setting
Number of subjects: 250
Study 18461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Triadic test-setting with another child observing
Number of subjects: 250
Study 18461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual test-setting within the noisy kindergarten group
Number of subjects: 250
Study 18461846 — intervention group
Group type: COMPARATOR
Intervention: Silent standard setting
Number of subjects: 250
Study 18461846 — intervention group
Group type: COMPARATOR
Intervention: Noisy setting with children playing loudly outside
Number of subjects: 250
Study 18461846 — intervention group
Group type: COMPARATOR
Intervention: Noisy setting with children singing loudly outside
Number of subjects: 250
Study 18461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Test time and social setting variations (after arrival, after joint breakfast, before and after joint lunch)
Number of subjects: 250
Study 16216827 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin 40 mug administered intravenously over 30 minutes
Number of subjects: 9
Study 16216827 — intervention group
Group type: COMPARATOR
Intervention: saline administered intravenously over 30 minutes
Number of subjects: 9
Study 12665160 — intervention group
Group type: EXPERIMENTAL
Intervention: Grippostad-C (acetaminophen, caffeine, chlorpheniramine, ascorbic acid)
Number of subjects: 1167
Study 12665160 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, caffeine, ascorbic acid (reference 2)
Number of subjects: 1167
Study 12665160 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and ascorbic acid (reference 1)
Number of subjects: 1167
Study 12665160 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (control)
Number of subjects: 1167
Study 11097610 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for RNFL measurements in normal eyes
Number of subjects: 20
Study 11097610 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for RNFL measurements in glaucoma eyes
Number of subjects: 20
Study 11097610 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model using three scans per patient for normal eyes
Number of subjects: 20
Study 11097610 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model using three scans per patient for glaucoma eyes
Number of subjects: 20
Study 11097610 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance analysis for RNFL measurements
Number of subjects: 20
Study 9461937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg rectally followed by 20 mg daily for 7 days
Number of subjects: 58
Study 9461937 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 40 mg rectally followed by 20 mg daily for 7 days
Number of subjects: 58
Study 1356851 — intervention group
Group type: EXPERIMENTAL
Intervention: Valethamate bromide
Number of subjects: 120
Study 1356851 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 120
Study 30199421 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2/HA
Number of subjects: 20
Study 30199421 — intervention group
Group type: COMPARATOR
Intervention: Bovine bone
Number of subjects: 20
Study 28546268 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based maintenance tele-rehabilitation
Number of subjects: 147
Study 28546268 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based outpatient maintenance rehabilitation
Number of subjects: 147
Study 28546268 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study 27101675 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP combined with modified oral appliance (MOA)
Number of subjects: 120
Study 27101675 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 120
Study 23746205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried purple carrot (118.5 mg/day of anthocyanins and 259.2 mg/day of phenolic acids for 4 weeks)
Number of subjects: 16
Study 20305399 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthine (0.3 microM, 1 microM, 3 microM, 10 microM, 30 microM, and 100 microM)
Number of subjects: 20
Study 20305399 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthine (subclinical <1 microM, therapeutic 3 microM to 30 microM, supratherapeutic 100 microM)
Number of subjects: 20
Study 19675107 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weight-loss maintainers (SWLs)
Number of subjects: 51
Study 19675107 — intervention group
Group type: COMPARATOR
Intervention: Obese controls
Number of subjects: 51
Study 19675107 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight (NW) controls
Number of subjects: 51
Study 16737761 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate infusion during 1h immediately after skin closure
Number of subjects: 20
Study 16737761 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion during 1h immediately after skin closure
Number of subjects: 20
Study 15381513 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention groups (two slightly different interventions)
Number of subjects: 338
Study 15381513 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338
Study 15381513 — intervention group
Group type: EXPERIMENTAL
Intervention: Original study groups (intervention groups)
Number of subjects: 338
Study 15381513 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-control group
Number of subjects: 338
Study 11380487 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 32
Study 11380487 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 32
Study 11380487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9640622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep
Number of subjects: 27
Study 9640622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8111140 — intervention group
Group type: EXPERIMENTAL
Intervention: New enterotropic peptide-based formula (NEF)
Number of subjects: 80
Study 8111140 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula (SEF)
Number of subjects: 80
Study 3317180 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg of epsilon‐aminocaproic acid (EACA), orally every 4 hours for 5 days (maximum 30 g/day)
Number of subjects: 49
Study 3317180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3317180 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 49
Study 29579763 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised homeopathic medicine
Number of subjects: 40
Study 29579763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27802493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography invitation for screening
Number of subjects: 19249
Study 27802493 — intervention group
Group type: COMPARATOR
Intervention: Control group without invitation
Number of subjects: 19249
Study 24550153 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based PA intervention based on MI with an avatar
Number of subjects: 0
Study 24550153 — intervention group
Group type: EXPERIMENTAL
Intervention: Content-identical intervention without an avatar
Number of subjects: 0
Study 24550153 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 0
Study 23072845 — intervention group
Group type: EXPERIMENTAL
Intervention: Homidium chloride
Number of subjects: 0
Study 23072845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminazene aceturate
Number of subjects: 0
Study 23072845 — intervention group
Group type: COMPARATOR
Intervention: Infected positive animals
Number of subjects: 0
Study 20145446 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management interventions
Number of subjects: 23
Study 20145446 — intervention group
Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 23
Study 18190370 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (24-page booklet)
Number of subjects: 330
Study 18190370 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 330
Study 16020212 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-IPL treatment
Number of subjects: 7
Study 16020212 — intervention group
Group type: COMPARATOR
Intervention: IPL treatment
Number of subjects: 7
Study 12942480 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructed ST-segment deviations (STdev) using mathematical formulas based on available leads on the 12-lead ECG.
Number of subjects: 1121
Study 12942480 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructed ST-segment resolution (STR) calculated from original data and from reconstructed STdev.
Number of subjects: 1121
Study 12942480 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate ST-segment resolution (STR) as an endpoint in trials.
Number of subjects: 1121
Study 10540045 — intervention group
Group type: EXPERIMENTAL
Intervention: OBTM (Omeprazole 20 mg b.d., Bismuth 120 mg q.d.s., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Number of subjects: 60
Study 10540045 — intervention group
Group type: EXPERIMENTAL
Intervention: RbcTM (Ranitidine bismuth citrate 400 mg b.d., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Number of subjects: 60
Study 8905425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (100 micrograms three times daily for 10 days)
Number of subjects: 39
Study 8905425 — intervention group
Group type: COMPARATOR
Intervention: Control group (no octreotide treatment)
Number of subjects: 39
Study 8905425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide
Number of subjects: 39
Study 1804603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Aspirin (50 mg/day)
Number of subjects: 0
Study 1804603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6136132 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 + H2-antagonists (Chlorpheniramine 4 X 4 mg/d and Cimetidine 4 X 400 mg/d for 4 weeks)
Number of subjects: 15
Study 6136132 — intervention group
Group type: COMPARATOR
Intervention: H1-antagonist alone (Chlorpheniramine 4 X 4 mg/d for 4 weeks)
Number of subjects: 15
Study 6136132 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 + H2-antagonists (Chlorpheniramine and Cimetidine for 4 weeks)
Number of subjects: 15
Study 6136132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6136132 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-antagonist (Chlorpheniramine)
Number of subjects: 15